A protein designed by Cedars-Sinai Cancer investigators can cross the protective blood-brain barrier safely and deliver therapy directly into cancerous tumor cells, a preclinical study shows.
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more
